Incidence of immune-related adverse events in U.S. veterans treated with immune checkpoint inhibitors.

Courtney KrallMarshall TagueBrian C Lund

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)

These findings are consistent with recent studies in clinical populations that demonstrate higher irAE incidence rates than originally reported in clinical trials. Our findings may enhance prompt recognition and treatment of irAEs for VA patients.

Keyphrases

clinical trial
end stage renal disease
newly diagnosed
risk factors
ejection fraction
peritoneal dialysis
prognostic factors
patient reported outcomes
smoking cessation